Purpose To determine whether neurochemical concentrations obtained at two MRI sites
using clinical 3T scanners can be pooled when a highly optimized, nonvendor short‐echo, …

Objective As gene-based therapies may soon arise for patients with spinocerebellar ataxia (SCA),
there is a critical need to identify biomarkers of disease progression with effect sizes …

Objective On the basis of our previous work with triheptanoin, which provides key substrates
to the Krebs cycle in the brain, we wished to assess its therapeutic effect in patients with …

Spinocerebellar ataxias (SCAs) belong to polyglutamine repeat disorders and are characterized
by a predominant atrophy of the cerebellum and the pons. Proton magnetic resonance …

The growing number of modalities (eg multi-omics, imaging and clinical data) characterizing
a given disease provides physicians and statisticians with complementary facets reflecting …

Background Spinal cord damage is a hallmark of Friedreich's ataxia (FRDA), but its
progression and clinical correlates remain unclear. Objective The objective of this study was to …

Development of imaging biomarkers for rare neurodegenerative diseases such as spinocerebellar
ataxia (SCA) is important to non-invasively track progression of disease pathology …

Friedreich ataxia is the most common hereditary ataxia. Atrophy of the spinal cord is one of
the hallmarks of the disease. MRI and magnetic resonance spectroscopy are powerful and …

Huntington’s disease (HD) is a monogenic, fully penetrant neurodegenerative disorder.
Widespread white matter damage affects the brain of patients with HD at very early stages of the …

Introduction Drug development for neurodegenerative diseases such as Friedreich’s ataxia (FRDA)
is limited by a lack of validated, sensitive biomarkers of pharmacodynamic response …